Puja Aggarwal
Cardinal Health (Ireland)(IE)Cardinal Health (United States)(US)
Publications by Year
Research Areas
Myeloproliferative Neoplasms: Diagnosis and Treatment, Multiple Myeloma Research and Treatments, Platelet Disorders and Treatments, Chronic Myeloid Leukemia Treatments, CAR-T cell therapy research
Most-Cited Works
- → Randomized Phase II Study of the Safety and Efficacy of Semorinemab in Participants With Mild-to-Moderate Alzheimer Disease: Lauriet(2023)98 cited
- → Lamotrigine use in pregnancy(2012)21 cited
- → Development of an infection‐resistant bifunctionalized Dacron biomaterial(2005)13 cited
- → Use of textile dyeing technology to create an infection‐resistant functionalized polyester biomaterial(2010)7 cited
- → Spontaneous recanalization of the basilar artery with conservative management months after symptom onset(2009)2 cited
- → Real-world treatment patterns and clinical outcomes in patients with myelofibrosis treated with pacritinib (PAC): Results from the my-PAC study(2025)
- → Real-World Patient Characteristics and Treatment Patterns in ALL Survivors with Relapsed/Refractory ALL(2024)
- → MPN-898: Real-World Treatment Patterns and Clinical Outcomes in Patients With Myelofibrosis Treated With Pacritinib With Platelets ≥50 × 109/L at Pacritinib Initiation: Interim Results From the MYPAC Study(2025)
- → Impact of minimal residual disease outcomes with ciltacabtagene autoleucel in cartitude-4: Oncologist treatment preferences in lenalidomide-refractory multiple myeloma(2025)
- → POSTER: MPN-898 Real-World Treatment Patterns and Clinical Outcomes in Patients With Myelofibrosis Treated With Pacritinib With Platelets ≥50 × 109/L at Pacritinib Initiation: Interim Results From the MY-PAC Study(2025)